• Products
  • Insights
  • Practice Management
  • Resources
  • About Us

Domestic Equity fund

Hartford Healthcare Fund   

SHARE CLASS
NAV
$43.45
NAV CHANGE
MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 9/30/2024)
158 PRODUCTS
Health Category
Based on Risk-Adjusted Returns
MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 9/30/2024)
158 PRODUCTS
Health Category
Based on Risk-Adjusted Returns
Key Documents
      Actions

      Domestic Equity fund

      Hartford Healthcare Fund   
      Share Class - I (HGHIX)

      Objective

      Seeks long-term capital appreciation.

      Overview

      A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.

      Portfolio Management
      Rebecca Sykes, CFA
      Senior Managing Director
      Global Industry Analyst
      4
      YRS
      MANAGING THIS FUND
      17
      YRS
      AT WELLINGTON MANAGEMENT
      19
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Wen Shi, CFA
      Managing Director
      Global Industry Analyst
      3
      YRS
      MANAGING THIS FUND
      9
      YRS
      AT WELLINGTON MANAGEMENT
      17
      YRS
      EXPERIENCE IN THIS INDUSTRY
      David Khtikian, CFA
      Managing Director
      Global Industry Analyst
      2
      YRS
      MANAGING THIS FUND
      11
      YRS
      AT WELLINGTON MANAGEMENT
      25
      YRS
      EXPERIENCE IN THIS INDUSTRY

      The portfolio managers are supported by the full resources of Wellington.

      Performance

      PERFORMANCE %
       
      CUMULATIVE %
      (as of 9/30/2024)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 9/30/2024)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare I 13.46 23.09 2.80 11.11 10.01 11.15
      Benchmark 14.01 21.46 7.44 12.91 11.15 ---
      Morningstar Health Category 10.57 21.36 -0.43 9.42 8.64 ---
       
      CUMULATIVE %
      (as of 9/30/2024)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 9/30/2024)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare I 13.46 23.09 2.80 11.11 10.01 11.15
      Benchmark 14.01 21.46 7.44 12.91 11.15 ---
      Morningstar Health Category 10.57 21.36 -0.43 9.42 8.64 ---

      Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

      SI = Since Inception. Fund Inception: 05/01/2000

      Share Class Inception: 8/31/06.
      Class I-share performance prior to its inception date reflects Class A-share performance (excluding sales charges) and operating expenses. SI performance is calculated from 5/1/00.

      Hartford Healthcare Fund I Share Morningstar Ratings
      Morningstar Medalist RatingTM
      9/26/2024
      overall
      (as of 9/30/2024)
      Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
      158 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      3 YEAR
      (as of 9/30/2024)
      Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
      158 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      5 YEAR
      (as of 9/30/2024)
      Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
      146 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      10 YEAR
      (as of 9/30/2024)
      Overall, 4 stars, 3-Year, 3 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 158, 158, 146 and 113 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
      113 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns

      Characteristics

      FUND ESSENTIALS
      Inception Date 05/01/2000
      Net Assets $1.1 billion
      Total Operating Expenses 1.01%
      Morningstar Category Health
      Lipper Classification Health/Biotechnology Funds
      CUSIP 416649887
      Fund Number 1309
      FUND STATS
      # of Holdings
      		100
      % in Equities
      		98
      % in Foreign Equities
      		17
      Beta (3 year)
      		1.00
      R Squared (3 year)
      		0.91
      Standard Deviation
      		15.32%
      Turnover
      		32%
      Active Share
      		49%
      Holdings Characteristics
      FUND S&P Composite 1500 Health Care Index
      Price/Earnings
      		28.5x 18.1x
      Price/Book
      		5.5x 5.2x
      EPS Growth Rate
      		21.7% 16.6%
      Asset Weighted Market Cap (billions)
      		$219.7 $268.4
      Return on Equity
      		19.0% 33.1%
      Median Market Cap (billions)
      		$11.1 $7.1
      Regional Exposure (%)
      North America 83
      Developed EU & Middle East ex UK 8
      Japan 4
      United Kingdom 4
      Emerging Markets 1
      North America 85
      Developed EU & Middle East ex UK 7
      United Kingdom 4
      Japan 4
      Emerging Markets 1
      Top Ten Holdings (%)
      Eli Lilly & Co. 10.89
      UnitedHealth Group, Inc. 8.91
      Merck & Co., Inc. 4.31
      Danaher Corp. 3.78
      Intuitive Surgical, Inc. 3.58
      Boston Scientific Corp. 3.44
      Thermo Fisher Scientific, Inc. 3.02
      Vertex Pharmaceuticals, Inc. 2.50
      HCA Healthcare, Inc. 2.31
      AstraZeneca PLC 1.88
      Total Portfolio % 44.62

      Full Portfolio Holdings
      Market Cap Distribution (%)

      Market Cap Header3
      Less than $2 billion 3
      $2 billion - $5 billion 7
      $5 billion - $10 billion 9
      Greater than $10 billion 81
      Not Classified 0
      RETURN CHARACTERISTICS
      Alpha (5 Year)
      		-1.53
      Down Capture (5 Year)
      		102.46
      Information Ratio (5 Year)
      		-0.35
      Sharpe Ratio (5 Year)
      		0.58
      Up Capture (5 Year)
      		95.84
      Subsector Exposure (%)
      Biopharma Large Cap 36
      Health Care Services 26
      Medical Technology 24
      Biopharma Mid Cap 11
      Biopharma Small Cap 3
      Biopharma Large Cap 37
      Medical Technology 23
      Health Care Services 23
      Biopharma Mid Cap 13
      Biopharma Small Cap 3
      Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
      distributions and capital gains
      Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
      12/27/2023 40.04 $0.0000 $0.0000 $0.0000 $0.0000
      12/11/2023 38.31 $0.0000 $0.0000 $0.0000 $0.0000
      Past distributions are not indicative of future distributions.

      Fund Literature

      VIEW MY SAVED ITEMS
      Fact Sheet
      09/30/2024 - PDF (179 KB)
      This client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance
      SUBSCRIBE
      ORDER PRINTS
      SAVEd
      Commentary
      09/30/2024 - PDF (142 KB)
      Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
      SUBSCRIBE
      ORDER PRINTS
      SAVEd
      Expanded Commentary
      09/30/2024 - PDF (265 KB)
      Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
      SUBSCRIBE
      ORDER PRINTS
      SAVEd
      Summary Prospectus
      PDF (157 KB)
      A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
      ORDER PRINTS
      SAVEd
      Pitchbook
      09/30/2024 - PDF (301 KB)
      This Pitchbook reviews the Fund's investment approach, investment team, investment process, and general portfolio parameters.
      SUBSCRIBE
      ORDER PRINTS
      SAVEd
      Financial Statements and Other Information – Semi-Annual
      PDF (3 KB)
      An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      SAVEd
      Statutory Prospectus
      PDF (13 KB)
      A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
      SAVEd
      Financial Statements and Other Information – Annual
      PDF (3 KB)
      An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      SAVEd
      SAI
      PDF (13 KB)
      A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
      SAVEd
      Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.
      3566488